Cover Image
市場調查報告書

癌症疫苗:技術和全球市場

Cancer Vaccines: Technologies and Global Markets

出版商 BCC Research 商品編碼 320804
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
癌症疫苗:技術和全球市場 Cancer Vaccines: Technologies and Global Markets
出版日期: 2016年11月14日 內容資訊: 英文 128 Pages
簡介

2014年的全球癌症疫苗市場成達近42億美元。該市場2015年約40億美金,預計從2016年到2021年的期間中以-0.4%的年複合成長率發展,2021年成為34億美元規模。

本報告提供全球癌症疫苗市場相關調查,全球市場癌症疫苗技術概要,市場趨勢的分析與預測,政府、法規環境的調查,市場影響因素及市場機會分析,專利趨勢,以及主要企業的簡介等彙整。

第1章 簡介

第2章 摘要整理

第3章 概要

  • 定義
  • 癌症的歷史與其管理
  • 癌症的原因
    • 遺傳的要素
    • 生活要素
    • 環境要素
  • 致癌遺傳基因的種類
  • 免疫系統和癌症
  • 癌症的分類
  • 癌症的預防
  • 癌症治療的種類
    • 手術
    • 放射治療
    • 化療
    • 免疫療法
    • 標靶治療
  • 癌症疫苗
    • 肝癌
    • 前列腺癌
    • 子宮頸癌
    • 癌症疫苗的平台

第4章 法規方面

  • 已經過核准癌症疫苗的法規的歷史
  • 回收
  • 孤兒藥指定
  • 迅速的指定

第5章 新的開發

  • 前列腺癌
  • 乳癌
  • 子宮頸癌
  • 肝癌
  • 肺癌
  • 胃癌
  • 大腸癌
  • 食道癌

第6章 癌症疫苗的市場分析

  • 市場:各類型
    • 市場概要
    • 市場收益
    • 市場佔有率
  • 市場:各地區
    • 市場概要
    • 市場收益
    • 治療用疫苗
    • 預防用疫苗

第7章 產業結構

  • 預防用癌症疫苗
  • 治療用癌症疫苗

第8章 按市場:適用

  • 全球市場:各種癌症的應用分類
  • 前列腺癌
  • 肝癌
  • 子宮頸癌疫苗
  • 其他癌症疫苗

第9章 專利分析

  • 各年度
  • 各類型/分類
  • 各企業
  • 各專利所有者的國家
  • 各申請類型

第10章 現狀

  • 癌症疫苗的影響因素
  • 癌症疫苗市場課題

第11章 企業簡介

  • ADAMIS PHARMACEUTICALS CORP.
  • ADURO BIOTECH INC.
  • ADVANTAGENE INC.
  • ADVAXIS INC.
  • ALPHAVAX INC.
  • ALTOR BIOSCIENCE CORP.
  • ANTIGEN EXPRESS INC.
  • BAVARIAN NORDIC A/S
  • BELLICUM PHARMACEUTICALS
  • BIOVEST INTERNATIONAL INC.
  • CASCADIAN THERAPEUTICS INC.
  • CELLDEX THERAPEUTICS
  • CUREVAC AG
  • DENDREON CORP.
  • EMD SERONO
  • GALENA BIOPHARMA INC.
  • GENEXINE INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE INC.
  • GRADALIS
  • HEAT BIOLOGICS INC.
  • IMMUNE CELL THERAPY INC. (ICT)
  • IMMUNICUM AB
  • IMMUNOVATIVE THERAPIES LTD.
  • INOVIO PHARMACEUTICALS
  • ISA PHARMACEUTICALS B.V.
  • GEMVAX & KAEL CO. LTD.
  • MERCK &CO.
  • NEWLINK GENETICS CORP.
  • NOVARX CORP.
  • ONCOVIR INC.
  • OXFORD BIOMEDICA PLC
  • SOTIO AS
  • UBIVAC LLC
  • VICAL INC.
  • VACCINOGEN INC.
  • VAXON BIOTECH

第12章 簡稱

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM173B

REPORT HIGHLIGHTS

The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.

This report provides:

  • An overview of the global markets and technologies for cancer vaccines.
  • Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of CAGRs through 2021.
  • Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
  • Examination of the governmental and regulatory environment and how its effecting the market.
  • Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
  • Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
  • Relevant patent analysis, presented by year and by vaccine type.
  • Profiles of major players in the industry.

SCOPE OF THE STUDY

The scope of this study entails the global market of cancer vaccines. The report covers the total market of cancer vaccines, which includes two main areas of applications, prophylactic vaccines and therapeutic vaccines. Human papillomavirus (HPV) vaccines and hepatitis B vaccines that indirectly act against cancer are also included in the report.

The report also covers the global market of cancer vaccines by application in various cancer types such as prostate, liver, cervical and others such as lung and urinary bladder. It is discussed from both a commercial perspective and that of a research and development (R&D) perspective.

BCC Research analyzes each market and its application, regulatory environment, new products and advancements, market projections and market shares. Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis and geographically sales are broken down into North America, Europe and emerging markets. The emerging market covers countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada among others.

Analysis of patents, clinical trials, innovations and opportunities the latest trends in the cancer vaccine market and comprehensive profiles of companies that lead the cancer vaccine industry are also discussed.

ANALYSTS' CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this report is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and she has worked with top companies in India and the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • DEFINITIONS
  • HISTORY OF CANCER AND ITS MANAGEMENT
    • TABLE 1: HISTORY OF CANCER AND ITS MANAGEMENT
  • CAUSES OF CANCER
    • GENETIC FACTORS
    • LIFESTYLE FACTORS
    • ENVIRONMENTAL FACTORS
  • TYPES OF CANCER-CAUSING GENES
  • IMMUNE SYSTEM AND CANCER
  • CLASSIFICATION OF CANCER
  • CANCER PREVENTION
  • TYPES OF CANCER TREATMENT
    • SURGERY
    • RADIATION THERAPY
    • CHEMOTHERAPY
    • IMMUNOTHERAPY
    • TARGETED THERAPY
  • CANCER VACCINES
    • LIVER CANCER
    • PROSTATE CANCER
      • Radical Retropubic Prostatectomy
      • Laparoscopic Prostatectomy
      • Radical Perineal Prostatectomy
      • Transurethral Resection of the Prostate
    • CERVICAL CANCER
    • CANCER VACCINES PLATFORM
      • Tumor Cell Vaccines
      • Cancer Stem Cell Vaccines
      • Peptide/Protein Vaccines
        • Antigen Vaccines
        • Anti-idiotype Vaccines
        • Heat Shock Protein Vaccines
        • DNA and Vector-Based Vaccines

CHAPTER 4 - REGULATORY ASPECTS

  • REGULATORY HISTORY OF APPROVED CANCER VACCINES
    • TABLE 2: REGULATORY APPROVALS OF CANCER VACCINES, JUNE 2006 TO OCT. 2015
  • RECALLS
    • TABLE 3: PRODUCT RECALLS, DECEMBER 2013
  • ORPHAN DRUG DESIGNATION
    • TABLE 4 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED, JAN. 2012 TO JUNE 2016
  • FAST TRACK DESIGNATIONS

CHAPTER 5 - NEW DEVELOPMENTS

  • PROSTATE CANCER
    • TABLE 5: CLINICAL TRIALS ON PROSTATE CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 6: SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
  • BREAST CANCER
    • TABLE 7: CLINICAL TRIALS ON BREAST CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 8: SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
  • CERVICAL CANCER
    • TABLE 9: CLINICAL TRIALS ON CERVICAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 10: SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
  • LIVER CANCER
    • TABLE 11: CLINICAL TRIALS ON LIVER CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 12: SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
  • LUNG CANCER
    • TABLE 13: CLINICAL TRIALS ON LUNG CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 14: SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER, AS OF JUNE 2016
  • STOMACH CANCER
    • TABLE 15: CLINICAL TRIALS ON STOMACH CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 16: SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
  • COLORECTAL CANCER
    • TABLE 17: CLINICAL TRIALS ON COLORECTAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 18: SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
  • ESOPHAGEAL CANCER
    • TABLE 19: CLINICAL TRIALS ON ESOPHAGEAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 20: SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016

CHAPTER 6 - MARKET ANALYSIS

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 21: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS)
      • FIGURE 1: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2014-2021 ($ MILLIONS)
    • MARKET SHARES
      • TABLE 22: MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)
      • FIGURE 2: MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 23: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 3: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
  • THERAPEUTIC VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 24: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 4: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • Market Share
      • TABLE 25: MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)
      • FIGURE 5: MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)
  • PROPHYLACTIC VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 26: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 6: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • Market Share
      • TABLE 27: PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)
      • FIGURE 7: PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)

CHAPTER 7 - INDUSTRY STRUCTURE

  • PROPHYLACTIC CANCER VACCINES
    • MARKET LEADERS
      • TABLE 28: LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2015
    • MARKET SHARE
      • TABLE 29: MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)
      • FIGURE 8: MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)
  • THERAPEUTIC CANCER VACCINES
    • MARKET LEADER
      • TABLE 30: LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2015
    • MARKET SHARE
      • TABLE 31: MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)
      • FIGURE 9: MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)

CHAPTER 8 - MARKET BY APPLICATION

  • GLOBAL MARKET FOR CANCER VACCINES BY APPLICATION IN VARIOUS CANCERS
    • MARKET REVENUES
      • TABLE 32: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2021 ($ MILLIONS)
      • FIGURE 10: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2014-2021 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 33: CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)
      • FIGURE 11: CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)
  • PROSTATE CANCER
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 24: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 12: GLOBAL MARKET FOR PROSTATE CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
  • LIVER CANCER
    • MARKET OVERVIEW
    • MARKET REVENUES
      • TABLE 35: GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 13: GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
  • CERVICAL CANCER VACCINES
    • MARKET OVERVIEW
    • MARKET REVENUES
      • TABLE 36: GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 14: GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
  • OTHER VACCINES FOR CANCER
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 37: GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 15: GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 9 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 38: U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)
    • FIGURE 16: U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)
  • PATENTS BY TYPE/CATEGORY
    • TABLE 39: U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)
    • FIGURE 17: U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)
  • PATENTS BY COMPANY
    • TABLE 40: U.S. PATENTS BY COMPANY, 2012 TO JUNE 2016 (NO.)
  • PATENTS BY COUNTRY
    • TABLE 41: U.S. PATENTS BY COUNTRY, 2012 TO JUNE 2016 (NO.)
    • TABLE 42: U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (NO./%)
    • FIGURE 18: U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (%)
  • PATENTS BY ASSIGNEE TYPE
    • TABLE 43: U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)
    • FIGURE 19: U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)

CHAPTER 10 - CURRENT SITUATION

  • FACTORS AFFECTING CANCER VACCINES
    • INCREASING PREVALENCE OF CANCER
    • AGING POPULATION
    • LIFESTYLE CHANGES
    • APPROVALS FOR ADDITIONAL INDICATIONS
    • COMPETITION
    • INCREASED FUNDING
    • MANUFACTURERS' STRATEGIES
  • CHALLENGES IN CANCER VACCINE MARKET

CHAPTER 11 - COMPANY PROFILES

  • ADAMIS PHARMACEUTICALS CORP.
  • ADURO BIOTECH INC.
  • ADVANTAGENE INC.
  • ADVAXIS INC.
  • ALPHAVAX INC.
  • ALTOR BIOSCIENCE CORP.
  • ANTIGEN EXPRESS INC.
  • BAVARIAN NORDIC A/S
  • BELLICUM PHARMACEUTICALS
  • BIOVEST INTERNATIONAL INC.
  • CASCADIAN THERAPEUTICS INC.
  • CELLDEX THERAPEUTICS
  • CUREVAC AG
  • DENDREON CORP.
  • EMD SERONO
  • GALENA BIOPHARMA INC.
  • GENEXINE INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE INC.
  • GRADALIS
  • HEAT BIOLOGICS INC.
  • IMMUNE CELL THERAPY INC. (ICT)
  • IMMUNICUM AB
  • IMMUNOVATIVE THERAPIES LTD.
  • INOVIO PHARMACEUTICALS
  • ISA PHARMACEUTICALS B.V.
  • GEMVAX & KAEL CO. LTD.
  • MERCK &CO.
  • NEWLINK GENETICS CORP.
  • NOVARX CORP.
  • ONCOVIR INC.
  • OXFORD BIOMEDICA PLC
  • SOTIO AS
  • UBIVAC LLC
  • VICAL INC.
  • VACCINOGEN INC.
  • VAXON BIOTECH

CHAPTER 12 - ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: HISTORY OF CANCER AND ITS MANAGEMENT
    • TABLE 2: REGULATORY APPROVALS OF CANCER VACCINES, JUNE 2006 TO OCT. 2015
    • TABLE 3: PRODUCT RECALLS, DECEMBER 2013
    • TABLE 4: SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED, JAN. 2012 TO JUNE 2016
    • TABLE 5: CLINICAL TRIALS ON PROSTATE CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 6: SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
    • TABLE 7: CLINICAL TRIALS ON BREAST CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 8: SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
    • TABLE 9: CLINICAL TRIALS ON CERVICAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 10: SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
    • TABLE 11: CLINICAL TRIALS ON LIVER CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 12: SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
    • TABLE 13: CLINICAL TRIALS ON LUNG CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 14: SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER, AS OF JUNE 2016
    • TABLE 15: CLINICAL TRIALS ON STOMACH CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 16: SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
    • TABLE 17: CLINICAL TRIALS ON COLORECTAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 18: SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
    • TABLE 19: CLINICAL TRIALS ON ESOPHAGEAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
    • TABLE 20: SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
    • TABLE 21: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 22: MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)
    • TABLE 23: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 24: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 25: MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)
    • TABLE 26: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 27: PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)
    • TABLE 28: LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2015
    • TABLE 29: MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)
    • TABLE 30: LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2015
    • TABLE 31: MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)
    • TABLE 32: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2021 ($ MILLIONS)
    • TABLE 33: CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)
    • TABLE 24: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 35: GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 36: GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 37: GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 38: U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)
    • TABLE 39: U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)
    • TABLE 40: U.S. PATENTS BY COMPANY, 2012 TO JUNE 2016 (NO.)
    • TABLE 41: U.S. PATENTS BY COUNTRY, 2012 TO JUNE 2016 (NO.)
    • TABLE 42: U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (NO./%)
    • TABLE 43: U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 1: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2014-2021 ($ MILLIONS)
    • FIGURE 2: MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)
    • FIGURE 3: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 4: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 5: MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)
    • FIGURE 6: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 7: PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)
    • FIGURE 8: MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)
    • FIGURE 9: MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)
    • FIGURE 10: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2014-2021 ($ MILLIONS)
    • FIGURE 11: CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)
    • FIGURE 12: GLOBAL MARKET FOR PROSTATE CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 13: GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 14: GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 15: GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
    • FIGURE 16: U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)
    • FIGURE 17: U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)
    • FIGURE 18: U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (%)
    • FIGURE 19: U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)
Back to Top